Acorda shares soar on possible patent extension of MS drug

BOSTON/BANGALORE Fri Apr 15, 2011 3:32am IST

Related Topics

Stocks

   

BOSTON/BANGALORE (Reuters) - Shares of Acorda Therapeutics Inc jumped 27 percent before being halted amid optimism the company will be granted a patent extension on its multiple sclerosis drug Ampyra.

The U.S. Patent and Trademark Office issued an update on its website titled "reasons for allowance" of Acorda's "828 " patent application.

Robert W. Baird & Co analyst Christopher Raymond , who termed the event as a "nice surprise , " said the patent extension will push the timeline of generic Ampyra launch beyond 2024.

"(Acorda) management is still waiting for confirmation from USPTO that a formal allowance is forthcoming , " Raymond , who raised his price target on the stock to $30 from $27 , said .

A spokesman for Acorda said the company has seen the USPTO update but declined to comment further.

According to Mark Schoenebaum, an analyst at ISI Group, the update "suggests the organization will grant the patent, but we are still working through the details."

Ampyra was approved by the U.S. Food and Drug Administration on January 22, 2010 and has

seven years of exclusivity in multiple sclerosis based on its orphan drug status.

The patent, if extended through to 2024, would be worth at least $10 a share, according to Michael Yee, an analyst at RBC Capital Markets.

Analysts see Ampyra reaching sales of around $871 million by 2015, according to Thomson Pharma consensus forecasts.

"We believe that IP (intellectual property) extension would be a significant catalyst for the shares and would make Acorda much more amenable to be an acquisition target," Yee said.

Acorda shares rose $5.71 to $27.13 before being halted on the Nasdaq stock market.

(Reporting by Toni Clarke in Boston and Anand Basu in Bangalore; editing by John Wallace)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

HEALTH SHOWCASE

Breast Cancer Fight

Breast Cancer Fight

Roche, Merck extend immunotherapy fight to breast cancer  Full Article 

Office Perks

Office Perks

Apple, Facebook will pay for female employees to freeze their eggs.  Full Article 

It's In The Genes

It's In The Genes

Genetic link to Danish happiness, says study.  Video 

Smoking Effects

Smoking Effects

Americans have 14 million smoking-related ailments: study.  Full Article 

Health Food

Health Food

Olive oil, nuts may help reverse heart risk factors.  Full Article 

Digital Doctors

Digital Doctors

China sees tech cure for healthcare woes.  Full Article 

Stem Cell Study

Stem Cell Study

Stem cells from human embryos prove safe, improve vision - study.  Full Article 

Shortages Impact

Shortages Impact

Shortages hinder Venezuela's battle against fever outbreaks  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage